INKT (MiNK Therapeutics) Buyback Yield %: -5.49 (As of Jul. 12, 2026)


INKT MiNK Therapeutics Inc INKT
34 GF Score
Price $11.04
! 2 Warning Signs
View Full Analysis

What is MiNK Therapeutics Buyback Yield %?

MiNK Therapeutics INKT -2.73% 34 Buyback Yield % is -5.49 as of Jul. 12, 2026. GuruFocus rates INKT with a GF Score™ of 34/100. The stock has 2 warning signs investors should review. Among 742 Biotechnology companies, MiNK Therapeutics ranks better than 57.95% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

MiNK Therapeutics's current buyback yield was -5.49%.

MiNK Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for MiNK Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MiNK Therapeutics Buyback Yield % Chart

MiNK Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Buyback Yield %
Get a 7-Day Free Trial -26.65 0.18 1.29 -21.00 -27.55

MiNK Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -27.55 -5.77

INKT vs BOLD, FLNA, DWTX: Buyback Yield % Comparison

For the Biotechnology subindustry, MiNK Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MiNK Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MiNK Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where MiNK Therapeutics's Buyback Yield % falls into.


INKT
34GF Score
MiNK Therapeutics Inc INKT
Buyback Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MiNK Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

MiNK Therapeutics's Buyback Yield for the fiscal year that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (0 + 14.455) / 52.4719
=-27.55%

MiNK Therapeutics's annualized Buyback Yield for the quarter that ended in Mar. 2026 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (0 + 3.02) / 52.32357
=-5.77%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -5.49 mean?
MiNK Therapeutics (INKT) has a Buyback Yield % of -5.49 as of Jul. 12, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MiNK Therapeutics and its competitors. According to the industry distribution chart, MiNK Therapeutics ranks #312 out of 742 companies in the Biotechnology industry, placing it in the top 42%.
Is MiNK Therapeutics' Buyback Yield % too high?
MiNK Therapeutics' current Buyback Yield % is -5.49. Based on the distribution chart, MiNK Therapeutics ranks #312 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, MiNK Therapeutics has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does MiNK Therapeutics' Buyback Yield % compare to BOLD and FLNA?
According to the Biotechnology industry distribution chart, MiNK Therapeutics ranks #312 out of 742 companies for Buyback Yield %. This puts MiNK Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on MiNK Therapeutics and its competitors. MiNK Therapeutics's current Buyback Yield % is -5.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiNK Therapeutics stock overvalued right now?
MiNK Therapeutics (INKT) has a current Buyback Yield % of -5.49. The current Buyback Yield % is -5.49. MiNK Therapeutics' overall GF Score™ is 34/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For MiNK Therapeutics (INKT), the current Buyback Yield % is -5.49 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MiNK Therapeutics Business Description

Other Exchanges 6Q40:Germany
Address 149 Fifth Avenue, Suite 500, New York, NY, USA, 10010
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development and manufacturing of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. iNKT cells offer distinct therapeutic advantages as a platform for allogeneic therapy in that the cells naturally home to tissues, aid clearance of tumors and infected cells, and suppress graft-versus-host-disease. Its product candidate, agenT-797, is an off-the-shelf, allogeneic, native iNKT cell therapy. It operates its business in single segment.
34GF Score

Get the complete analysis for INKT

Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$11.04
Price